Active Not Recruiting PHASE3 INTERVENTIONAL 3-arm NCT06143878

A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

Sponsor: Janssen Research & Development, LLC

Conditions Plaque Psoriasis

Interventions Deucravacitinib Deucravacitinib Matching Placebo JNJ-77242113 JNJ-77242113 Matching Placebo

Updated 25 times since 2023 Last updated: Mar 11, 2026 Started: Feb 1, 2024 Primary completion: Sep 17, 2024 Completion: Jun 1, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Plaque Psoriasis, this trial is ongoing. The trial is conducted by Janssen Research & Development, LLC and has accumulated 25 data snapshots since 2024. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

25 versions recorded

Mar 2026 — Present [monthly]

Active Not Recruiting PHASE3
Feb 2026 — Mar 2026 [monthly]

Active Not Recruiting PHASE3
Dec 2025 — Feb 2026 [monthly]

Active Not Recruiting PHASE3
Nov 2025 — Dec 2025 [monthly]

Active Not Recruiting PHASE3
Oct 2025 — Nov 2025 [monthly]

Active Not Recruiting PHASE3

▶ Show 20 earlier versions

Sep 2025 — Oct 2025 [monthly]

Active Not Recruiting PHASE3
Aug 2025 — Sep 2025 [monthly]

Active Not Recruiting PHASE3
Jun 2025 — Aug 2025 [monthly]

Active Not Recruiting PHASE3
May 2025 — Jun 2025 [monthly]

Active Not Recruiting PHASE3
Apr 2025 — May 2025 [monthly]

Active Not Recruiting PHASE3
Mar 2025 — Apr 2025 [monthly]

Active Not Recruiting PHASE3
Feb 2025 — Mar 2025 [monthly]

Active Not Recruiting PHASE3
Jan 2025 — Feb 2025 [monthly]

Active Not Recruiting PHASE3
Nov 2024 — Jan 2025 [monthly]

Active Not Recruiting PHASE3
Oct 2024 — Nov 2024 [monthly]

Active Not Recruiting PHASE3
Sep 2024 — Oct 2024 [monthly]

Active Not Recruiting PHASE3
Aug 2024 — Sep 2024 [monthly]

Active Not Recruiting PHASE3

Status: Recruiting → Active Not Recruiting
Jul 2024 — Aug 2024 [monthly]

Recruiting PHASE3
Jun 2024 — Jul 2024 [monthly]

Recruiting PHASE3
May 2024 — Jun 2024 [monthly]

Recruiting PHASE3
Apr 2024 — May 2024 [monthly]

Recruiting PHASE3
Mar 2024 — Apr 2024 [monthly]

Recruiting PHASE3

Status: Not Yet Recruiting → Recruiting
Feb 2024 — Mar 2024 [monthly]

Not Yet Recruiting PHASE3
Jan 2024 — Feb 2024 [monthly]

Not Yet Recruiting PHASE3
Dec 2023 — Jan 2024 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Janssen Research & Development, LLC

Data source: Janssen Research & Development, LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ajax, Canada , Alicante, Spain , Alpharetta, United States , Ann Arbor, United States , Athens, United States , Barakaldo, Spain , Barcelona, Spain , Barrie, Canada , Berlin, Germany , Bialystok, Poland and 126 more locations